Nabriva Therapeutics AG (NASDAQ: NBRV) and Seattle Genetics (NASDAQ:SGEN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares Nabriva Therapeutics AG and Seattle Genetics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nabriva Therapeutics AG N/A -90.54% -72.82%
Seattle Genetics -47.38% -32.87% -25.17%

Risk and Volatility

Nabriva Therapeutics AG has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500. Comparatively, Seattle Genetics has a beta of 2.38, indicating that its stock price is 138% more volatile than the S&P 500.

Institutional & Insider Ownership

68.6% of Nabriva Therapeutics AG shares are owned by institutional investors. Comparatively, 97.6% of Seattle Genetics shares are owned by institutional investors. 2.8% of Nabriva Therapeutics AG shares are owned by insiders. Comparatively, 34.7% of Seattle Genetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Nabriva Therapeutics AG and Seattle Genetics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Nabriva Therapeutics AG $6.01 million 39.61 -$59.30 million ($2.45) -3.62
Seattle Genetics $428.94 million 17.64 -$187.25 million ($1.43) -36.99

Nabriva Therapeutics AG has higher revenue, but lower earnings than Seattle Genetics. Seattle Genetics is trading at a lower price-to-earnings ratio than Nabriva Therapeutics AG, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Nabriva Therapeutics AG and Seattle Genetics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nabriva Therapeutics AG 0 0 7 0 3.00
Seattle Genetics 2 9 7 0 2.28

Nabriva Therapeutics AG presently has a consensus target price of $19.71, suggesting a potential upside of 122.26%. Seattle Genetics has a consensus target price of $61.25, suggesting a potential upside of 15.81%. Given Nabriva Therapeutics AG’s stronger consensus rating and higher probable upside, equities analysts clearly believe Nabriva Therapeutics AG is more favorable than Seattle Genetics.

Summary

Seattle Genetics beats Nabriva Therapeutics AG on 7 of the 12 factors compared between the two stocks.

About Nabriva Therapeutics AG

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin. Lefamulin is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. Lefamulin is being evaluated in two global, registrational Phase III clinical trials in patients with moderate to severe community-acquired bacterial pneumonia (CABP).It seeks to further pursue development of lefamulin for additional indications, including the treatment of acute bacterial skin and skin structure infections (ABSSSI), and is developing a formulation of lefamulin appropriate for pediatric use.

About Seattle Genetics

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company’s pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.

Receive News & Stock Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related stocks with our FREE daily email newsletter.